Denali Therapeutics (DNLI) Interest & Investment Income (2023 - 2026)
Denali Therapeutics (DNLI) reported Interest & Investment Income of $8.9 million for Q1 2026, down 29.34% year-over-year from $12.6 million in Q1 2025, and little changed on a QoQ basis from $8.9 million in Q4 2025.
Denali Therapeutics (DNLI) has 4 years of Interest & Investment Income data on file, last reported at $8.9 million in Q1 2026.
- Quarterly Interest & Investment Income fell 29.34% year-over-year to $8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.2 million (down 36.08% YoY) and the FY2025 annual result came in at $42.9 million, down 33.62% from the prior year.
- Interest & Investment Income held at $8.9 million in Q1 2026 per DNLI's latest filing, from $8.9 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $17.6 million in Q2 2024 and bottomed at $8.9 million in Q1 2026.
- The 4-year median for Interest & Investment Income is $12.9 million (2023), against an average of $12.9 million.
- The widest annual swing landed in 2024, when Interest & Investment Income soared 44.22%; it then tumbled 41.18% in 2025.
- Tracing DNLI's Interest & Investment Income over 4 years: stood at $13.1 million in 2023, then advanced by 15.48% to $15.2 million in 2024, then plunged by 41.18% to $8.9 million in 2025, then fell by 0.09% to $8.9 million in 2026.
- Per Business Quant, the three latest DNLI Interest & Investment Income figures stand at $8.9 million (Q1 2026), $8.9 million (Q4 2025), and $10.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | 8.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.91 Mn |
| Dec 31, 2025 | 8.92 Mn |
| Sep 30, 2025 | 10.53 Mn |
| Jun 30, 2025 | 10.84 Mn |
| Mar 31, 2025 | 12.61 Mn |
| Dec 31, 2024 | 15.16 Mn |
| Sep 30, 2024 | 16.00 Mn |
| Jun 30, 2024 | 17.57 Mn |
| Mar 31, 2024 | 15.91 Mn |
| Dec 31, 2023 | 13.13 Mn |
| Sep 30, 2023 | 14.44 Mn |
| Jun 30, 2023 | 12.90 Mn |
| Mar 31, 2023 | 11.03 Mn |